<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00455767</url>
  </required_header>
  <id_info>
    <org_study_id>DEB-EPIV-201</org_study_id>
    <secondary_id>2006-000756-41 (EUDRACT NR)</secondary_id>
    <nct_id>NCT00455767</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Depelestat in Acute Respiratory Distress Syndrome (ARDS) Patients</brief_title>
  <official_title>Phase IIA Multicenter 1 Week Treatment, Randomised, Double-Blind, Placebo Controlled Study of Depelestat in Patients Suffering From Acute Respiratory Distress Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Debiopharm International SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Debiopharm International SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is aimed to assess safety of Depelestat treatment, as well as efficacy on
      prevention and treatment of alveolar inflammation in early pulmonary fibrosis in patients
      suffering from persistent Acute Respiratory Distress Syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, randomised, double-blind, parallel groups, placebo-controlled, 1 week
      treatment of Depelestat, in patients suffering from persistent ARDS.

      Patients admitted in the intensive care unit presenting ARDS criteria persistent for 12 hours
      to 24 hours, will be randomly assigned to the treatment by Depelestat or placebo, after a
      pre-treatment period as short as possible with a maximum of 48 hours since ARDS criteria are
      met. During the pre-treatment period, the informed consent will be obtained from the legally
      authorized relative of the patient, and pre-treatment biological and functional examinations
      will be performed, particularly blood samples and BAL for biological parameters measurement,
      and ventilatory mechanics, for assessment of static compliance of the respiratory system.

      After the pre-treatment period, the patient will receive treatment by Depelestat or placebo
      during 7 days, or until extubation of the patient if this occurs before 7 days of treatment.
      During this treatment period, the patient will be submitted to a daily measurement of static
      compliance of the respiratory system, as long as the patient adaptation to 24 hours after
      mechanical ventilation allows the procedure, and at 96 initiation of treatment, to a blood
      sampling and a bronchoalveolar lavage for several biological parameters assessment.

      On the first and last day of administration, blood will be also collected for pharmacokinetic
      evaluation.

      During the post-treatment period, the patient will be submitted, at 48 h ± 24 h after the end
      of treatment, to a blood sampling and a BAL (this BAL is not performed when contraindication
      criteria are present, if the patient is already extubated, and in case of planed extubation
      during the subsequent 24 hours) for several biological parameters assessment, and a daily
      measurement of static compliance as long as the patient adaptation to mechanical ventilation
      allows the procedure. Patients already extubated will not be submitted to BAL nor to static
      compliance measurements.

      After the end of the treatment, patients will be followed daily for 28 days after the
      diagnostic of ARDS, or until death whichever occurred first.

      The duration of the study for each survivor patient will be 28 days. Survivors to day 28 will
      be contacted monthly to assess survival and fill in a QOL questionnaire on days 60 and 90.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Static compliance relative change from pre-treatment to last on treatment</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>PCPIII and cytokines concentration, as well as neutrophil influx relative change in BAL fluid from pre-treatment to post-treatment</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Fibrosis</condition>
  <condition>Lung Disease</condition>
  <condition>Respiratory Disorders</condition>
  <condition>Respiratory Distress Syndrome, Adult</condition>
  <condition>Acute Respiratory Distress Syndrome</condition>
  <condition>Pulmonary Fibrosis</condition>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Depelestat</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EPI-hNE4</intervention_name>
    <description>I.V. injection of 1mg/kg Depelestat (EPI-hNE4) 3 times daily for 7 days</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients suffering from persistent ARDS as defined by the American and European
             Consensus Conference on ARDS, 1994

        Exclusion Criteria:

          -  ARDS secondary to traumatism

          -  Pulmonary emphysema on pulmonary fibrosis

          -  Lung pneumocystosis

          -  Bronchopleural fistula

          -  Systemic corticosteroid treatment for more than 2 weeks before inclusion

          -  Severe organ disease excepted renal
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>François Saudubray, MD</last_name>
    <role>Study Director</role>
    <affiliation>Debiopharm SA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alain Mercat</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yves Castaing</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laurent Brochard</name>
      <address>
        <city>Créteil Cedex</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jean-François Timsit</name>
      <address>
        <city>Grenoble Cedex 09</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Claude Guerin</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samir Jaber</name>
      <address>
        <city>Montpellier Cedex 05</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jean-Yves Fagon</name>
      <address>
        <city>Paris Cedex 15</city>
        <zip>75908</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jean-Daniel Chiche</name>
      <address>
        <city>Paris Cedex</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jean-Jacques Rouby</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jean-Christophe Richard</name>
      <address>
        <city>Rouen Cedex</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jean-Michel Arnal</name>
      <address>
        <city>Toulon</city>
        <zip>83100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massimo Antonelli</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jordi Mancebo D.</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fekri Abroug</name>
      <address>
        <city>Monastir</city>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>Tunisia</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/</url>
  </link>
  <reference>
    <citation>Honoré S, Attalah HL, Azoulay E, Soussy CJ, Saudubray F, Harf A, Brochard L, Delclaux C. Beneficial effect of an inhibitor of leukocyte elastase (EPI-hNE-4) in presence of repeated lung injuries. Shock. 2004 Aug;22(2):131-6.</citation>
    <PMID>15257085</PMID>
  </reference>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2007</study_first_submitted>
  <study_first_submitted_qc>April 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2007</study_first_posted>
  <last_update_submitted>June 23, 2008</last_update_submitted>
  <last_update_submitted_qc>June 23, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2008</last_update_posted>
  <responsible_party>
    <name_title>François Saudubray, M.D.</name_title>
    <organization>Debiopharm S.A.</organization>
  </responsible_party>
  <keyword>persistent ARDS</keyword>
  <keyword>alveolar inflammation</keyword>
  <keyword>early pulmonary fibrosis</keyword>
  <keyword>mechanichal ventilation</keyword>
  <keyword>P/V curve</keyword>
  <keyword>Static compliance</keyword>
  <keyword>elastase activity</keyword>
  <keyword>inhibitor of Human Neutrophil Elastase</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

